myocardial infarction

repatha
Pharma

Amgen doesn't think Repatha's sales wins will stop anytime soon

With Repatha and several other key growth drivers, Amgen has outpaced declines from biosimilar competition to key brands in Q2.
Fraiser Kansteiner Aug 4, 2026 4:01pm